Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia

PURPOSE: The anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel (CTL019) has an 81% response rate in children with relapsed or chemotherapy refractory (r/r) B-cell acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is a life-threatening treatment-related toxicity th...

Full description

Saved in:
Bibliographic Details
Published in:J Clin Oncol
Main Authors: Frey, Noelle V., Shaw, Pamela A., Hexner, Elizabeth O., Pequignot, Edward, Gill, Saar, Luger, Selina M., Mangan, James K., Loren, Alison W., Perl, Alexander E., Maude, Shannon L., Grupp, Stephan A., Shah, Nirav N., Gilmore, Joan, Lacey, Simon F., Melenhorst, Jos J., Levine, Bruce L., June, Carl H., Porter, David L.
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2020
Subjects:
ORIGINAL REPORTS
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8312030/
https://ncbi.nlm.nih.gov/pubmed/31815579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01892
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items